Olr415 inhibitors represent a specific category of chemical compounds that are designed to selectively bind to and inhibit the activity of the Olr415 receptor, a member of the olfactory receptor family. Olfactory receptors, including Olr415, are G-protein-coupled receptors (GPCRs) primarily expressed in the olfactory epithelium. These receptors are responsible for detecting volatile chemical signals, contributing to the sense of smell by transducing chemical stimuli into neural signals. The Olr415 receptor, in particular, is one of the numerous olfactory receptors in mammals, each with the potential to recognize specific odorants. Inhibitors targeting Olr415 are typically designed to interfere with the receptor's ability to bind to its natural ligands, thereby modulating the signal transduction pathway and altering the perception of specific odors.
The structural design of Olr415 inhibitors often involves the precise manipulation of molecular features to achieve high affinity and selectivity for the receptor. This involves the consideration of molecular docking studies, where potential inhibitors are modeled to fit into the receptor's binding pocket. Such studies help identify key interactions between the inhibitor and the receptor, such as hydrogen bonding, hydrophobic interactions, and van der Waals forces. Additionally, the chemical properties of Olr415 inhibitors, such as their solubility, stability, and bioavailability in non-clinical settings, are of significant interest in the context of research focusing on the basic understanding of olfactory signaling pathways. The investigation into these inhibitors not only sheds light on the specific roles of the Olr415 receptor but also contributes to broader insights into the complex mechanisms underlying olfactory perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ambrisentan | 177036-94-1 | sc-207276 | 5 mg | $348.00 | ||
Endothelin receptor antagonist, may indirectly affect GPCR signaling through endothelin pathway modulation, impacting Olr415. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Non-selective beta-adrenergic blocker, can modulate GPCR signaling pathways, potentially affecting Olr415. | ||||||
Dabigatran | 211914-51-1 | sc-481166 | 5 mg | $205.00 | 1 | |
Direct thrombin inhibitor, might influence GPCR signaling indirectly through coagulation pathway effects, impacting Olr415. | ||||||
Edoxaban | 480449-70-5 | sc-483508 | 25 mg | $522.00 | ||
Factor Xa inhibitor, could alter GPCR signaling indirectly via anticoagulant activity, impacting Olr415. | ||||||
Ivabradine hydrochloride | 148849-67-6 | sc-507513 | 10 mg | $120.00 | ||
If channel inhibitor, can modulate GPCR signaling indirectly through cardiac electrophysiological effects, impacting Olr415. | ||||||
Nebivolol | 99200-09-6 | sc-279910 | 100 mg | $803.00 | 1 | |
Beta-1 adrenergic receptor antagonist, could influence GPCR signaling pathways, potentially impacting Olr415. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $155.00 | 18 | |
Anticoagulant, can influence GPCR signaling indirectly through coagulation pathway modulation, impacting Olr415. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $39.00 $90.00 $120.00 | 4 | |
Angiotensin II receptor antagonist, could alter GPCR signaling indirectly, potentially impacting Olr415. | ||||||